Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Feb 7, 2019 • 4:01 PM EST
Ligand Reports Fourth Quarter and Full Year 2018 Financial Results
Feb 7, 2019 • 9:00 AM EST
Ligand Announces OmniAb® Partnership with Genagon Therapeutics
Feb 4, 2019 • 4:01 PM EST
Ligand Announces Investment in Dianomi Therapeutics
Feb 7, 2019 • 4:30pm EST
See all events
Nov 8, 2018 • 9:00am EST
Nov 7, 2018 • 1:00pm EST
New York, NY
Daiichi Sankyo announces Japan approval of MINNEBRO (esaxerenone) tablets for the treatment of hypertension… https://t.co/3h6lVu3MkP
$CRVS to present updated biomarker and clinical data on CPI-444 at Immuno-Oncology 360° Conference https://t.co/prICFYY9wd
Verona Pharma receives WHO approval for “ensifentrine” as recommended INN name for RPL554 https://t.co/BFNSFg4UuM